{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:28:05Z","timestamp":1793363285062,"version":"4.5.0"},"reference-count":158,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":1877,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mesenchymal stem cells (MSCs) represent a potentially revolutionary therapy for a wide variety of pediatric diseases, but the optimal cell-based therapeutics for such diversity have not yet been specified. The published clinical trials for pediatric pulmonary, cardiac, orthopedic, endocrine, neurologic, and hematologic diseases provide evidence that MSCs are indeed efficacious, but the significant heterogeneity in therapeutic approaches between studies raises new questions. The purpose of this review is to stimulate new preclinical and clinical trials to investigate these factors. First, we discuss recent clinical trials for pediatric diseases studying MSCs obtained from bone marrow, umbilical cord and umbilical cord blood, placenta, amniotic fluid, and adipose tissue. We then identify factors, some unique to pediatrics, which must be examined to optimize therapeutic efficacy, including route of administration, dose, timing of administration, the role of ex vivo differentiation, cell culture techniques, donor factors, host factors, and the immunologic implications of allogeneic therapy. Finally, we discuss some of the practicalities of bringing cell-based therapy into the clinic, including regulatory and manufacturing considerations. The aim of this review is to inform future studies seeking to maximize therapeutic efficacy for each disease and for each patient.<\/jats:p>","DOI":"10.5966\/sctm.2015-0427","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T21:59:19Z","timestamp":1473803959000},"page":"539-565","source":"Crossref","is-referenced-by-count":51,"title":["Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements"],"prefix":"10.1093","volume":"6","author":[{"given":"Christopher R.","family":"Nitkin","sequence":"first","affiliation":[{"name":"a Division of Neonatology, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey L.","family":"Bonfield","sequence":"additional","affiliation":[{"name":"b Division of Pulmonology, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA"},{"name":"c Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"2022022809290064300_R1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jor.1100090504","article-title":"Mesenchymal stem cells","volume":"9","author":"Caplan","year":"1991","journal-title":"J Orthop Res"},{"key":"2022022809290064300_R2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2011.06.008","article-title":"The MSC: An injury drugstore","volume":"9","author":"Caplan","year":"2011","journal-title":"Cell Stem Cell"},{"key":"2022022809290064300_R3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4236\/scd.2013.32019","article-title":"Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease","volume":"3","author":"Bonfield","year":"2013","journal-title":"Stem Cell Discov"},{"key":"2022022809290064300_R4","doi-asserted-by":"crossref","first-page":"L760","DOI":"10.1152\/ajplung.00182.2009","article-title":"Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model","volume":"299","author":"Bonfield","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2022022809290064300_R5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1164\/rccm.200902-0242OC","article-title":"Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease","volume":"180","author":"Aslam","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2022022809290064300_R6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/thoraxjnl-2012-202323","article-title":"Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia","volume":"68","author":"Pierro","year":"2013","journal-title":"Thorax"},{"key":"2022022809290064300_R7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0034-1382777","article-title":"Tissue engineering approaches in skeletal pediatric disorders","volume":"24","author":"Gentili","year":"2014","journal-title":"Eur J Pediatr Surg"},{"key":"2022022809290064300_R8","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1582-4934.2011.01265.x","article-title":"Bone regeneration: Stem cell therapies and clinical studies in orthopaedics and traumatology","volume":"15","author":"G\u00f3mez-Barrena","year":"2011","journal-title":"J Cell Mol Med"},{"key":"2022022809290064300_R9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/pr.2011.68","article-title":"Mesenchymal stem cells in osteoarticular pediatric diseases: An update","volume":"71","author":"Norambuena","year":"2012","journal-title":"Pediatr Res"},{"key":"2022022809290064300_R10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/joor.12079","article-title":"Mesenchymal stem cells in oral reconstructive surgery: A systematic review of the literature","volume":"40","author":"Jakobsen","year":"2013","journal-title":"J Oral Rehabil"},{"key":"2022022809290064300_R11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s13577-014-0095-x","article-title":"Mesenchymal stem cell therapy and acute graft-versus-host disease: A review","volume":"27","author":"Amorin","year":"2014","journal-title":"Hum Cell"},{"issue":"suppl 4","key":"2022022809290064300_R12","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/j.placenta.2011.04.013","article-title":"Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review)","volume":"32","author":"McGuirk","year":"2011","journal-title":"Placenta"},{"key":"2022022809290064300_R13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.55782\/ane-2013-1920","article-title":"Human mesenchymal stem cells in the treatment of neurological diseases","volume":"73","author":"Drela","year":"2013","journal-title":"Acta Neurobiol Exp (Warsz)"},{"key":"2022022809290064300_R14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.clp.2013.09.002","article-title":"Stem cell therapy for neonatal brain injury","volume":"41","author":"Fleiss","year":"2014","journal-title":"Clin Perinatol"},{"key":"2022022809290064300_R15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.spen.2013.06.002","article-title":"The potential for stem cells in cerebral palsy\u2013\u2013piecing together the puzzle","volume":"20","author":"Faulkner","year":"2013","journal-title":"Semin Pediatr Neurol"},{"key":"2022022809290064300_R16","first-page":"50","article-title":"Stem cells and their mediators\u2014next generation therapy for bronchopulmonary dysplasia","volume":"2","author":"M\u00f6bius","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"2022022809290064300_R17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/pr.2011.61","article-title":"Stem cell therapy for cardiac disease","volume":"71","author":"Bernstein","year":"2012","journal-title":"Pediatr Res"},{"key":"2022022809290064300_R18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R19","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2174\/1381612811319130015","article-title":"Mesenchymal stem\/stromal cells: A new \u201ccells as drugs\u201d paradigm. Efficacy and critical aspects in cell therapy","volume":"19","author":"de Girolamo","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2022022809290064300_R20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cyto.a.22402","article-title":"Human adult stem cells from diverse origins: An overview from multiparametric immunophenotyping to clinical applications","volume":"85","author":"Sousa","year":"2014","journal-title":"Cytometry A"},{"key":"2022022809290064300_R21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fimmu.2015.00560","article-title":"Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells","volume":"6","author":"Mattar","year":"2015","journal-title":"Front Immunol"},{"key":"2022022809290064300_R22","doi-asserted-by":"crossref","first-page":"e00191","DOI":"10.1042\/BSR20150025","article-title":"Human mesenchymal stem cells\u2014current trends and future prospective","volume":"35","author":"Ullah","year":"2015","journal-title":"Biosci Rep"},{"key":"2022022809290064300_R23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007890-196803000-00009","article-title":"Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues","volume":"6","author":"Friedenstein","year":"1968","journal-title":"Transplantation"},{"key":"2022022809290064300_R24","first-page":"381","article-title":"Osteogenesis in transplants of bone marrow cells","volume":"16","author":"Friedenstein","year":"1966","journal-title":"J Embryol Exp Morphol"},{"key":"2022022809290064300_R25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"2022022809290064300_R26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-2141.1999.01715.x","article-title":"Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate","volume":"107","author":"Digirolamo","year":"1999","journal-title":"Br J Haematol"},{"key":"2022022809290064300_R27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/art.10118","article-title":"Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis","volume":"46","author":"Murphy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022022809290064300_R28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S8756-3282(02)00820-7","article-title":"Cooperative actions of hepatocyte growth factor and 1,25-dihydroxyvitamin D3 in osteoblastic differentiation of human vertebral bone marrow stromal cells","volume":"31","author":"D\u2019Ippolito","year":"2002","journal-title":"Bone"},{"key":"2022022809290064300_R29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bone.2003.07.005","article-title":"Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells","volume":"33","author":"Stenderup","year":"2003","journal-title":"Bone"},{"key":"2022022809290064300_R30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.mad.2007.12.002","article-title":"Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies","volume":"129","author":"Stolzing","year":"2008","journal-title":"Mech Ageing Dev"},{"key":"2022022809290064300_R31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1164\/rccm.201306-1043OC","article-title":"Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response","volume":"189","author":"Bustos","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2022022809290064300_R32"},{"key":"2022022809290064300_R33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat Med"},{"key":"2022022809290064300_R34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta","volume":"97","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"2022022809290064300_R35","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022022809290064300_R36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1359\/jbmr.2003.18.4.624","article-title":"Marrow cell transplantation for infantile hypophosphatasia","volume":"18","author":"Whyte","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2022022809290064300_R37","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00198-015-3272-1","article-title":"Hypophosphatasia: An overview of the disease and its treatment","volume":"26","author":"Bianchi","year":"2015","journal-title":"Osteoporos Int"},{"key":"2022022809290064300_R38","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/archinte.162.14.1558","article-title":"Allogeneic hematopoietic stem cell transplantation: Complications and results","volume":"162","author":"Tabbara","year":"2002","journal-title":"Arch Intern Med"},{"key":"2022022809290064300_R39","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","article-title":"Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis","volume":"3","author":"Hashmi","year":"2016","journal-title":"Lancet Haematol"},{"key":"2022022809290064300_R40","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"key":"2022022809290064300_R41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.12545","article-title":"Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease","volume":"163","author":"Ball","year":"2013","journal-title":"Br J Haematol"},{"key":"2022022809290064300_R42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","article-title":"Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients","volume":"20","author":"Kurtzberg","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809290064300_R43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: A phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809290064300_R44"},{"key":"2022022809290064300_R45"},{"key":"2022022809290064300_R46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1703650","article-title":"Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)","volume":"30","author":"Ko\u00e7","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"2022022809290064300_R47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbmt.2004.06.001","article-title":"Replacement of recipient stromal\/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells","volume":"10","author":"Cahill","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809290064300_R48","first-page":"951","article-title":"Hypotonia and neuromuscular disease in the neonate","volume-title":"Fanaroff and Martin's Neonatal-Perinatal Medicine","author":"Bass","year":"2015","edition":"10th ed."},{"key":"2022022809290064300_R49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PHM.0000000000000309","article-title":"Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1","volume":"94","author":"Villanova","year":"2015","journal-title":"Am J Phys Med Rehabil"},{"key":"2022022809290064300_R50","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1089\/scd.2013.0016","article-title":"Mesenchymal stromal cell characteristics vary depending on their origin","volume":"22","author":"Wegmeyer","year":"2013","journal-title":"Stem Cells Dev"},{"key":"2022022809290064300_R51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/ten.teb.2013.0664","article-title":"Umbilical cord mesenchymal stem cells: The new gold standard for mesenchymal stem cell based therapies?","volume":"20","author":"El Omar","year":"2014","journal-title":"Tissue Eng Part B Rev"},{"key":"2022022809290064300_R52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3727\/096368914X678300","article-title":"Umbilical cord blood: A trustworthy source of multipotent stem cells for regenerative medicine","volume":"23","author":"Jaing","year":"2014","journal-title":"Cell Transplant"},{"key":"2022022809290064300_R53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.earlhumdev.2011.12.013","article-title":"Outcomes of extremely low birth weight infants with bronchopulmonary dysplasia: Impact of the physiologic definition","volume":"88","author":"Natarajan","year":"2012","journal-title":"Early Hum Dev"},{"key":"2022022809290064300_R54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1542\/peds.2009-2959","article-title":"Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network","volume":"126","author":"Stoll","year":"2010","journal-title":"Pediatrics"},{"key":"2022022809290064300_R55","first-page":"1157","article-title":"Bronchopulmonary dysplasia in the neonate","volume-title":"Fanaroff and Martin's Neonatal-Perinatal Medicine","author":"Bancalari","year":"2015","edition":"10th ed."},{"key":"2022022809290064300_R56","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jpeds.2013.12.011","article-title":"Mesenchymal stem cells for bronchopulmonary dysplasia: Phase 1 dose-escalation clinical trial","volume":"164","author":"Chang","year":"2014","journal-title":"J Pediatr"},{"key":"2022022809290064300_R57"},{"key":"2022022809290064300_R58","doi-asserted-by":"crossref","first-page":"325652","DOI":"10.1155\/2015\/325652","article-title":"Safety of allogeneic umbilical cord blood stem cells therapy in patients with severe cerebral palsy: A retrospective study","volume":"2015","author":"Feng","year":"2015","journal-title":"Stem Cells Int"},{"key":"2022022809290064300_R59","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jcyt.2015.02.010","article-title":"Human allogeneic AB0\/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy","volume":"17","author":"Romanov","year":"2015","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R60","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1089\/scd.2015.0074","article-title":"Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy","volume":"24","author":"Kang","year":"2015","journal-title":"Stem Cells Dev"},{"key":"2022022809290064300_R61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-5-30","article-title":"Stem cell therapy for autism","volume":"5","author":"Ichim","year":"2007","journal-title":"J Transl Med"},{"key":"2022022809290064300_R62","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1479-5876-11-196","article-title":"Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism","volume":"11","author":"Lv","year":"2013","journal-title":"J Transl Med"},{"key":"2022022809290064300_R63","first-page":"75","article-title":"Human placental stem cells: Biomedical potential and clinical relevance","volume":"6","author":"Malek","year":"2011","journal-title":"J Stem Cells"},{"key":"2022022809290064300_R64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/stem.1314","article-title":"Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease","volume":"31","author":"Ringd\u00e9n","year":"2013","journal-title":"Stem Cells"},{"issue":"suppl","key":"2022022809290064300_R65","first-page":"I64","article-title":"Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source","volume":"116","author":"Schmidt","year":"2007","journal-title":"Circulation"},{"key":"2022022809290064300_R66","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1177\/0300060513487640","article-title":"Amniotic stem cell transplantation therapy for type 1 diabetes: A case report","volume":"41","author":"Liu","year":"2013","journal-title":"J Int Med Res"},{"key":"2022022809290064300_R67","doi-asserted-by":"crossref","first-page":"6737345","DOI":"10.1155\/2016\/6737345","article-title":"Adipose-derived stem cells for tissue engineering and regenerative medicine applications","volume":"2016","author":"Dai","year":"2016","journal-title":"Stem Cells Int"},{"key":"2022022809290064300_R68","doi-asserted-by":"crossref","first-page":"3206807","DOI":"10.1155\/2016\/3206807","article-title":"Advances in adipose-derived stem cells isolation, characterization, and application in regenerative tissue engineering","volume":"2016","author":"Wankhade","year":"2016","journal-title":"Stem Cells Int"},{"key":"2022022809290064300_R69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/107632701300062859","article-title":"Multilineage cells from human adipose tissue: Implications for cell-based therapies","volume":"7","author":"Zuk","year":"2001","journal-title":"Tissue Eng"},{"key":"2022022809290064300_R70","first-page":"149","article-title":"From bench to bedside: Use of human adipose-derived stem cells","volume":"8","author":"Feisst","year":"2015","journal-title":"Stem Cells Cloning"},{"key":"2022022809290064300_R71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tibtech.2006.01.010","article-title":"Fat tissue: An underappreciated source of stem cells for biotechnology","volume":"24","author":"Fraser","year":"2006","journal-title":"Trends Biotechnol"},{"key":"2022022809290064300_R72","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1399-3046.2007.00780.x","article-title":"Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children","volume":"11","author":"Fang","year":"2007","journal-title":"Pediatr Transplant"},{"key":"2022022809290064300_R73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/2006-8808.78465","article-title":"Split calvarial bone graft for the reconstruction of skull defects","volume":"3","author":"Agrawal","year":"2011","journal-title":"J Surg Tech Case Rep"},{"key":"2022022809290064300_R74","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcms.2004.06.002","article-title":"Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: Case report","volume":"32","author":"Lendeckel","year":"2004","journal-title":"J Craniomaxillofac Surg"},{"key":"2022022809290064300_R75","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0032-1320067","article-title":"Craniofacial microsomia","volume":"26","author":"Birgfeld","year":"2012","journal-title":"Semin Plast Surg"},{"key":"2022022809290064300_R76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PRS.0b013e3182910a82","article-title":"Fat grafts supplemented with adipose-derived stromal cells in the rehabilitation of patients with craniofacial microsomia","volume":"132","author":"Tanikawa","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"2022022809290064300_R77","doi-asserted-by":"crossref","first-page":"200226","DOI":"10.1136\/bcr-2013-200226","article-title":"Management of type 1 diabetes mellitus using in vitro autologous adipose tissue trans-differentiated insulin-making cells","volume":"2013","author":"Dave","year":"2013","journal-title":"BMJ Case Rep"},{"key":"2022022809290064300_R78","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.transproceed.2008.03.113","article-title":"Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin","volume":"40","author":"Trivedi","year":"2008","journal-title":"Transplant Proc"},{"key":"2022022809290064300_R79","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/scd.2008.0253","article-title":"Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect","volume":"18","author":"Fischer","year":"2009","journal-title":"Stem Cells Dev"},{"key":"2022022809290064300_R80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fimmu.2012.00297","article-title":"Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion","volume":"3","author":"Eggenhofer","year":"2012","journal-title":"Front Immunol"},{"key":"2022022809290064300_R81","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.nucmedbio.2011.03.008","article-title":"In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis","volume":"38","author":"Gholamrezanezhad","year":"2011","journal-title":"Nucl Med Biol"},{"key":"2022022809290064300_R82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/scd.2014.0265","article-title":"Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling","volume":"24","author":"Erkers","year":"2015","journal-title":"Stem Cells Dev"},{"key":"2022022809290064300_R83","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcyt.2014.09.010","article-title":"Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: Pilot study on the correlation of efficacy and hereditary factors","volume":"17","author":"Wang","year":"2015","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R84","doi-asserted-by":"crossref","first-page":"623875","DOI":"10.1155\/2013\/623875","article-title":"Autologous bone marrow mononuclear cell therapy for autism: An open label proof of concept study","volume":"2013","author":"Sharma","year":"2013","journal-title":"Stem Cells Int"},{"key":"2022022809290064300_R85","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1161\/CIR.0b013e31821b1f10","article-title":"Indications for cardiac catheterization and intervention in pediatric cardiac disease: A scientific statement from the American Heart Association","volume":"123","author":"Feltes","year":"2011","journal-title":"Circulation"},{"key":"2022022809290064300_R86"},{"key":"2022022809290064300_R87","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1399-3046.2008.01024.x","article-title":"Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy","volume":"13","author":"Rupp","year":"2009","journal-title":"Pediatr Transplant"},{"key":"2022022809290064300_R88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1399-3046.2009.01215.x","article-title":"Peripheric stem cell transplantation in children with dilated cardiomyopathy: Preliminary report of first two cases","volume":"14","author":"Olgunt\u00fcrk","year":"2010","journal-title":"Pediatr Transplant"},{"key":"2022022809290064300_R89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1017\/S1047951110001435","article-title":"Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy","volume":"21","author":"Lacis","year":"2011","journal-title":"Cardiol Young"},{"key":"2022022809290064300_R90","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/petr.12055","article-title":"Follow-up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy","volume":"17","author":"Bergmane","year":"2013","journal-title":"Pediatr Transplant"},{"key":"2022022809290064300_R91","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.hfc.2010.05.002","article-title":"The pediatric cardiomyopathy registry and heart failure: Key results from the first 15 years","volume":"6","author":"Wilkinson","year":"2010","journal-title":"Heart Fail Clin"},{"key":"2022022809290064300_R92","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jcyt.2013.06.001","article-title":"Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: A preliminary clinical study","volume":"15","author":"Wang","year":"2013","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R93","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4252\/wjsc.v6.i2.195","article-title":"Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility","volume":"6","author":"Nagamura-Inoue","year":"2014","journal-title":"World J Stem Cells"},{"key":"2022022809290064300_R94","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2009.03.040","article-title":"Secondary repair of alveolar clefts using human mesenchymal stem cells","volume":"108","author":"Behnia","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2022022809290064300_R95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jcms.2011.02.003","article-title":"Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: A preliminary report","volume":"40","author":"Behnia","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"2022022809290064300_R96","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ijom.2005.12.007","article-title":"Alveolar cleft osteoplasty using tissue-engineered osteogenic material","volume":"35","author":"Hibi","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2022022809290064300_R97","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow\u2013derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial [published correction appears in JAMA 2013;310:750]","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"2022022809290064300_R98","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1210\/jc.2006-2131","article-title":"Infantile hypophosphatasia: Transplantation therapy trial using bone fragments and cultured osteoblasts","volume":"92","author":"Cahill","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022022809290064300_R99","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jpeds.2008.12.021","article-title":"New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia","volume":"154","author":"Tadokoro","year":"2009","journal-title":"J Pediatr"},{"key":"2022022809290064300_R100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1479-5876-11-21","article-title":"Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy","volume":"11","author":"Chen","year":"2013","journal-title":"J Transl Med"},{"key":"2022022809290064300_R101","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s11999-015-4192-2","article-title":"Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro","volume":"473","author":"Sch\u00e4r","year":"2015","journal-title":"Clin Orthop Relat Res"},{"issue":"suppl 1","key":"2022022809290064300_R102","first-page":"s214","article-title":"Bio-modulators in platelet-rich plasma: A comparison of the amounts in products from healthy donors and patients produced with three different techniques","volume":"12","author":"Ubezio","year":"2014","journal-title":"Blood Transfus"},{"key":"2022022809290064300_R103","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.aanat.2013.04.004","article-title":"Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors","volume":"195","author":"Anitua","year":"2013","journal-title":"Ann Anat"},{"key":"2022022809290064300_R104","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fphys.2015.00290","article-title":"The influence of platelet-derived products on angiogenesis and tissue repair: A concise update","volume":"6","author":"Mart\u00ednez","year":"2015","journal-title":"Front Physiol"},{"key":"2022022809290064300_R105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.32098\/mltj.01.2014.02","article-title":"Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives","volume":"4","author":"Dohan Ehrenfest","year":"2014","journal-title":"Muscles Ligaments Tendons J"},{"key":"2022022809290064300_R106","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5966\/sctm.2015-0094","article-title":"Xeno-free extraction, culture, and cryopreservation of human adipose-derived mesenchymal stem cells","volume":"5","author":"Escobar","year":"2016","journal-title":"Stem Cells Translational Medicine"},{"key":"2022022809290064300_R107","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jcyt.2013.11.004","article-title":"Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells","volume":"16","author":"Hemeda","year":"2014","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R108","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/scrt477","article-title":"Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton's jelly derived mesenchymal stem cells? A comparative study","volume":"5","author":"Swamynathan","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"2022022809290064300_R109","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12967-015-0561-6","article-title":"Scalable efficient expansion of mesenchymal stem cells in xeno free media using commercially available reagents","volume":"13","author":"Riordan","year":"2015","journal-title":"J Transl Med"},{"key":"2022022809290064300_R110","doi-asserted-by":"crossref","first-page":"16570","DOI":"10.1038\/srep16570","article-title":"Optimization of human mesenchymal stem cell manufacturing: The effects of animal\/xeno-free media","volume":"5","author":"Oikonomopoulos","year":"2015","journal-title":"Sci Rep"},{"key":"2022022809290064300_R111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13287-015-0016-2","article-title":"Culture of human mesenchymal stem cells using a candidate pharmaceutical grade xeno-free cell culture supplement derived from industrial human plasma pools","volume":"6","author":"D\u00edez","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"2022022809290064300_R112","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2471\/BLT.10.080010","article-title":"Blood sample volumes in child health research: Review of safe limits","volume":"89","author":"Howie","year":"2011","journal-title":"Bull World Health Organ"},{"key":"2022022809290064300_R113","doi-asserted-by":"crossref","first-page":"951512","DOI":"10.1155\/2014\/951512","article-title":"Mesenchymal stem cells for regenerative therapy: Optimization of cell preparation protocols","volume":"2014","author":"Ikebe","year":"2014","journal-title":"Biomed Res Int"},{"key":"2022022809290064300_R114","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cryobiol.2015.07.003","article-title":"Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects","volume":"71","author":"Marquez-Curtis","year":"2015","journal-title":"Cryobiology"},{"key":"2022022809290064300_R115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbmt.2011.07.023","article-title":"Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy","volume":"18","author":"von Bahr","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809290064300_R116","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1089\/scd.2010.0566","article-title":"Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats","volume":"21","author":"Waszak","year":"2012","journal-title":"Stem Cells Dev"},{"key":"2022022809290064300_R117","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12967-014-0260-8","article-title":"A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods","volume":"12","author":"Madrigal","year":"2014","journal-title":"J Transl Med"},{"key":"2022022809290064300_R118","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/cgt.2010.4","article-title":"Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: An exploratory study","volume":"17","author":"Garc\u00eda-Castro","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"2022022809290064300_R119","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1097\/MPH.0000000000000084","article-title":"Superselective intracerebral catheterization for administration of oncolytic virotherapy in a case of diffuse intrinsic pontine glioma","volume":"36","author":"Carceller","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"2022022809290064300_R120","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1111\/ped.12012","article-title":"Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia","volume":"55","author":"Taketani","year":"2013","journal-title":"Pediatr Int"},{"key":"2022022809290064300_R121","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/ten.teb.2011.0488","article-title":"Therapeutic applications of mesenchymal stromal cells: Paracrine effects and potential improvements","volume":"18","author":"Doorn","year":"2012","journal-title":"Tissue Eng Part B Rev"},{"key":"2022022809290064300_R122","doi-asserted-by":"crossref","first-page":"965849","DOI":"10.1155\/2014\/965849","article-title":"Prospect of stem cell conditioned medium in regenerative medicine","volume":"2014","author":"Pawitan","year":"2014","journal-title":"Biomed Res Int"},{"key":"2022022809290064300_R123","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pr.2012.152","article-title":"Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury","volume":"73","author":"Sutsko","year":"2013","journal-title":"Pediatr Res"},{"key":"2022022809290064300_R124","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/2045-8932.97603","article-title":"Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension","volume":"2","author":"Hansmann","year":"2012","journal-title":"Pulm Circ"},{"key":"2022022809290064300_R125","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mt.2015.44","article-title":"Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic applications","volume":"23","author":"Rani","year":"2015","journal-title":"Mol Ther"},{"key":"2022022809290064300_R126","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12015-014-9545-9","article-title":"A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles","volume":"11","author":"Akyurekli","year":"2015","journal-title":"Stem Cell Rev"},{"key":"2022022809290064300_R127","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.3390\/ijms15034142","article-title":"Exosomes derived from mesenchymal stem cells","volume":"15","author":"Yu","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2022022809290064300_R128","doi-asserted-by":"crossref","first-page":"30087","DOI":"10.3402\/jev.v4.30087","article-title":"Applying extracellular vesicles based therapeutics in clinical trials\u2014an ISEV position paper","volume":"4","author":"Lener","year":"2015","journal-title":"J Extracell Vesicles"},{"key":"2022022809290064300_R129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/stem.1504","article-title":"Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice","volume":"32","author":"Zhu","year":"2014","journal-title":"Stem Cells"},{"key":"2022022809290064300_R130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1479-5876-12-8","article-title":"Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation","volume":"12","author":"Choudhery","year":"2014","journal-title":"J Transl Med"},{"key":"2022022809290064300_R131","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1741-7015-11-146","article-title":"Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells","volume":"11","author":"Siegel","year":"2013","journal-title":"BMC Med"},{"key":"2022022809290064300_R132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.transci.2006.05.012","article-title":"Effect of the ABO blood group on the proliferative and clonogenic capacity of umbilical cord stem cells","volume":"35","author":"Galan","year":"2006","journal-title":"Transfus Apheresis Sci"},{"key":"2022022809290064300_R133","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: Immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2022022809290064300_R134","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/rme.15.14","article-title":"Immunogenicity of allogeneic mesenchymal stromal cells: What has been seen in vitro and in vivo?","volume":"10","author":"Consentius","year":"2015","journal-title":"Regen Med"},{"key":"2022022809290064300_R135"},{"key":"2022022809290064300_R136"},{"key":"2022022809290064300_R137"},{"key":"2022022809290064300_R138"},{"key":"2022022809290064300_R139","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-18618-4","volume-title":"Regulatory Aspects of Gene Therapy and Cell Therapy Products","author":"Galli","year":"2015"},{"key":"2022022809290064300_R140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/scrt129","article-title":"US Food and Drug Administration international collaborations for cellular therapy product regulation","volume":"3","author":"Arcidiacono","year":"2012","journal-title":"Stem Cell Res Ther"},{"key":"2022022809290064300_R141"},{"key":"2022022809290064300_R142","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.molmed.2015.02.008","article-title":"US stem cell clinics, patient safety, and the FDA","volume":"21","author":"Turner","year":"2015","journal-title":"Trends Mol Med"},{"key":"2022022809290064300_R143","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.addr.2014.12.001","article-title":"From bench to FDA to bedside: US regulatory trends for new stem cell therapies","volume":"82-83","author":"Knoepfler","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"2022022809290064300_R144"},{"key":"2022022809290064300_R145"},{"key":"2022022809290064300_R146"},{"key":"2022022809290064300_R147","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3109\/14653249.2010.532663","article-title":"Cell therapy medical tourism: Time for action","volume":"12","author":"Gunter","year":"2010","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R148"},{"key":"2022022809290064300_R149","first-page":"285","article-title":"Bone marrow derived stem cells in regenerative medicine as advanced therapy medicinal products","volume":"2","author":"Astori","year":"2010","journal-title":"Am J Transl Res"},{"key":"2022022809290064300_R150","first-page":"193519","article-title":"Translating research into clinical scale manufacturing of mesenchymal stromal cells","volume":"2010","author":"Bieback","year":"2011","journal-title":"Stem Cells Int"},{"key":"2022022809290064300_R151","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.imlet.2015.06.006","article-title":"Clinical grade expansion of MSCs","volume":"168","author":"Capelli","year":"2015","journal-title":"Immunol Lett"},{"key":"2022022809290064300_R152","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/scrt217","article-title":"Production of mesenchymal stromal\/stem cells according to good manufacturing practices: A review","volume":"4","author":"Senseb\u00e9","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"2022022809290064300_R153","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcyt.2014.04.002","article-title":"Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications","volume":"17","author":"Wuchter","year":"2015","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R154","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcyt.2013.03.005","article-title":"Risk of tumorigenicity in mesenchymal stromal cell-based therapies\u2013\u2013bridging scientific observations and regulatory viewpoints","volume":"15","author":"Barkholt","year":"2013","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R155","doi-asserted-by":"crossref","first-page":"974","DOI":"10.5966\/sctm.2015-0071","article-title":"Our fat future: Translating adipose stem cell therapy","volume":"4","author":"Nordberg","year":"2015","journal-title":"Stem Cells Translational Medicine"},{"key":"2022022809290064300_R156","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jcyt.2015.02.002","article-title":"Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments","volume":"17","author":"Vives","year":"2015","journal-title":"Cytotherapy"},{"key":"2022022809290064300_R157","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1014379","article-title":"A randomized trial of prenatal versus postnatal repair of myelomeningocele","volume":"364","author":"Adzick","year":"2011","journal-title":"N Engl J Med"},{"key":"2022022809290064300_R158","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5966\/sctm.2011-0027","article-title":"The Alpha Stem Cell Clinic: A model for evaluating and delivering stem cell-based therapies","volume":"1","author":"Trounson","year":"2012","journal-title":"Stem Cells Translational Medicine"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/2\/539\/42631139\/stcltm_6_2_539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/2\/539\/42631139\/stcltm_6_2_539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T06:19:17Z","timestamp":1718777957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/6\/2\/539\/6404795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":158,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,9,13]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2015-0427","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2016,9,13]]}}}